Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

Immunogenicity and safety of vaccination against seasonal influenza vaccine in patients with psoriatic arthritis treated with secukinumab.

Furer V, Zisman D, Kaufman I, Arad U, Berman M, Sarbagil-Maman H, Elias M, Hadad A, Paran D, Drori Y, Friedman N, Mandelboim M, Elkayam O.

Vaccine. 2019 Nov 22. pii: S0264-410X(19)31470-7. doi: 10.1016/j.vaccine.2019.10.081. [Epub ahead of print]

PMID:
31767465
2.

Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD.

Furer V, Rondaan C, Heijstek M, van Assen S, Bijl M, Agmon-Levin N, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, Ladefoged de Thurah A, Landewé R, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.

RMD Open. 2019 Sep 19;5(2):e001041. doi: 10.1136/rmdopen-2019-001041. eCollection 2019.

3.

Prevalence of high-sensitivity cardiac troponin T in real-life cohorts of psoriatic arthritis and general population: a cross-sectional study.

Furer V, Shenhar-Tsarfaty S, Berliner S, Arad U, Paran D, Mailis I, Rogowski O, Zeltser D, Shapira I, Matz H, Elkayam O.

Rheumatol Int. 2019 Oct 23. doi: 10.1007/s00296-019-04461-y. [Epub ahead of print]

PMID:
31646356
4.

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations.

Rondaan C, Furer V, Heijstek MW, Agmon-Levin N, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, Ladefoged de Thurah A, Landewé R, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, van Assen S, Elkayam O.

RMD Open. 2019 Sep 9;5(2):e001035. doi: 10.1136/rmdopen-2019-001035. eCollection 2019.

5.

Adherence to Treat-to-Target Management in Rheumatoid Arthritis and Associated Factors: Data from the International RA BIODAM Cohort.

Sepriano A, Ramiro S, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Elkayam O, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Landewé R, Maksymowych WP.

J Rheumatol. 2019 Sep 15. pii: jrheum.190303. doi: 10.3899/jrheum.190303. [Epub ahead of print]

PMID:
31523049
6.

[RITUXIMAB IN RHEUMATOID ARTHRITIS - THERAPEUTIC ASPECTS BASED ON 18 YEARS OF GLOBAL EXPERIENCE].

Zisapel M, Paran D, Elkayam O.

Harefuah. 2019 Sep;158(9):595-600. Review. Hebrew.

PMID:
31507112
7.

[RHEUMATOLOGY IN ISRAEL - THE PLATINUM ERA].

Abu-Shakra M, Uziel Y, Elkayam O.

Harefuah. 2019 Sep;158(9):559-562. Hebrew.

PMID:
31507103
8.

The International RA BIODAM Cohort for Validation of Soluble Biomarkers in Rheumatoid Arthritis: Cohort Description.

Maksymowych WP, FitzGerald O, Østergaard M, Homik J, van der Heijde D, Lambert RG, Elkayam O, Ramiro S, Thorne C, Larché MJ, Ferraccioli G, Backhaus M, Burmester GR, Boire G, Combe B, Saraux A, Dougados M, Rossini M, Govoni M, Sinigaglia L, Cantagrel A, Allaart R, Barnabe C, Bingham CO 3rd, Tak PP, van Schaardenburg D, Hammer HB, Paschke J, Dadashova R, Hutchings E, Sepriano A, Landewé R.

J Rheumatol. 2019 Sep 1. pii: jrheum.190302. doi: 10.3899/jrheum.190302. [Epub ahead of print]

PMID:
31474600
9.

2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.

Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, van Laar JM, de Thurah A, Landewé RB, Molto A, Müller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O.

Ann Rheum Dis. 2019 Aug 14. pii: annrheumdis-2019-215882. doi: 10.1136/annrheumdis-2019-215882. [Epub ahead of print]

PMID:
31413005
10.

Treat-to-target concept implementation for evaluating rheumatoid arthritis patients in daily practice.

Gazitt T, Oren S, Reitblat T, Lidar M, Gurman AB, Rosner I, Halabe N, Feld J, Kassem S, Lavi I, Elkayam O, Zisman D.

Eur J Rheumatol. 2019 May 20;6(3):136-141. doi: 10.5152/eurjrheum.2019.18195.

11.

Association of Serum Tocilizumab Trough Concentrations with Clinical Disease Activity Index Scores in Adult Patients with Rheumatoid Arthritis.

Arad U, Elkayam O.

J Rheumatol. 2019 Dec;46(12):1577-1581. doi: 10.3899/jrheum.181431. Epub 2019 Jun 1.

PMID:
31154416
12.

Paraneoplastic Dactylitis Leading to the Diagnosis of Ovarian Cancer.

Eviatar T, Elkayam O.

Isr Med Assoc J. 2019 May;5(21):354-355. No abstract available.

13.

The Effect of Pregnancy on Disease Activity in Patients with Psoriatic Arthritis.

Berman M, Zisman D, Wollman J, Levartovsky D, Rimon E, Elkayam O, Paran D.

J Rheumatol. 2018 Dec;45(12):1651-1655. doi: 10.3899/jrheum.171218. Epub 2018 Sep 15.

PMID:
30219770
14.

Evaluating IBD-specific antiglycan antibodies in serum of patients with spondyloarthritis and rheumatoid arthritis: are they really specific?

Aloush V, Dotan I, Ablin JN, Elkayam O.

Clin Exp Rheumatol. 2019 Jan-Feb;37(1):32-36. Epub 2018 Jun 25.

PMID:
29998822
15.

Elevated Levels of Eotaxin-2 in Serum of Fibromyalgia Patients.

Furer V, Hazan E, Mor A, Segal M, Katav A, Aloush V, Elkayam O, George J, Ablin JN.

Pain Res Manag. 2018 May 13;2018:7257681. doi: 10.1155/2018/7257681. eCollection 2018.

16.

Heparanase is expressed in adult human osteoarthritic cartilage and drives catabolic responses in primary chondrocytes.

Gibor G, Ilan N, Journo S, Sharabi A, Dreyer J, Gertel S, Singh P, Menachem A, Snir N, Elkayam O, Vlodavsky I, Arad U.

Osteoarthritis Cartilage. 2018 Aug;26(8):1110-1117. doi: 10.1016/j.joca.2018.05.013. Epub 2018 May 24.

17.

The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients.

Sthoeger Z, Sharabi A, Asher I, Zinger H, Segal R, Shearer G, Elkayam O, Mozes E.

Clin Immunol. 2018 Jul;192:85-91. doi: 10.1016/j.clim.2018.05.001. Epub 2018 May 4.

PMID:
29730433
18.

Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug.

Danino O, Svetitsky S, Kenigsberg S, Levin A, Journo S, Gold A, Drexler M, Snir N, Elkayam O, Fischer B, Arad U.

Rheumatology (Oxford). 2018 Aug 1;57(8):1472-1480. doi: 10.1093/rheumatology/key092.

PMID:
29688536
19.

Expression levels of selected genes can predict individual rheumatoid arthritis patient response to tumor necrosis factor alpha blocker treatment.

Paran D, Smith Y, Pundak S, Arad U, Levartovsky D, Kaufman I, Wollman J, Furer V, Broyde A, Elalouf O, Caspi D, Pel S, Elkayam O.

Curr Med Res Opin. 2018 Oct;34(10):1777-1783. doi: 10.1080/03007995.2018.1443581. Epub 2018 Mar 23.

PMID:
29569514
20.

Sputum Anticitrullinated Protein Antibodies in Patients With Long-standing Rheumatoid Arthritis.

Polachek A, Vree Egberts W, Fireman E, Druckman I, Stark M, Paran D, Kaufman I, Wigler I, Levartovsky D, Caspi D, Pruijn GJM, Elkayam O.

J Clin Rheumatol. 2018 Apr;24(3):122-126. doi: 10.1097/RHU.0000000000000619.

PMID:
29200020
21.
22.

[PRECLINICAL RHEUMATOID ARTHRITIS].

Elalouf O, Elkayam O.

Harefuah. 2017 Jul;156(7):451-454. Review. Hebrew.

PMID:
28786276
23.

Rituximab as a Second-Line Treatment for Lymphocytic Vasculitis of the Central Nervous System.

Anis S, Sharabi A, Mina Y, Klein A, Cagnano E, Elkayam O, Gurevich T.

Isr Med Assoc J. 2016 Oct;18(10):630-632. No abstract available.

24.

Magnetic resonance imaging in diffuse idiopathic skeletal hyperostosis: similarities to axial spondyloarthritis.

Arad U, Elkayam O, Eshed I.

Clin Rheumatol. 2017 Jul;36(7):1545-1549. doi: 10.1007/s10067-017-3617-6. Epub 2017 Mar 31.

PMID:
28364275
25.

Authors' reply.

Furer V, Zisman D, Pokroy-Shapira E, Molad Y, Elkayam O, Paran D.

Scand J Rheumatol. 2017 May;46(3):251-252. doi: 10.1080/03009742.2016.1264628. Epub 2017 Feb 16. No abstract available.

PMID:
28276956
26.

Self-Reported Childhood Maltreatment and Traumatic Events among Israeli Patients Suffering from Fibromyalgia and Rheumatoid Arthritis.

Hellou R, Häuser W, Brenner I, Buskila D, Jacob G, Elkayam O, Aloush V, Ablin JN.

Pain Res Manag. 2017;2017:3865249. doi: 10.1155/2017/3865249. Epub 2017 Jan 11.

27.

Cocaine-Induced Vasculitis.

Berman M, Paran D, Elkayam O.

Rambam Maimonides Med J. 2016 Oct 31;7(4). doi: 10.5041/RMMJ.10263. Review.

28.

Implementation of recommendations for the screening of hydroxychloroquine retinopathy: poor adherence of rheumatologists and ophthalmologists.

Shulman S, Wollman J, Brikman S, Padova H, Elkayam O, Paran D.

Lupus. 2017 Mar;26(3):277-281. doi: 10.1177/0961203316660204. Epub 2016 Jul 21.

PMID:
27440459
29.

Prevalence of Axial Spondyloarthritis Among Patients With Fibromyalgia: A Magnetic Resonance Imaging Study With Application of the Assessment of SpondyloArthritis International Society Classification Criteria.

Ablin JN, Eshed I, Berman M, Aloush V, Wigler I, Caspi D, Likhter M, Wollman J, Paran D, Anouk M, Elkayam O.

Arthritis Care Res (Hoboken). 2017 May;69(5):724-729. doi: 10.1002/acr.22967.

30.

Induced Sputum Analysis in Subjects With Systemic Sclerosis.

Litinsky I, Fireman E, Paran D, Polachek A, Broide A, Sharabi A, Anouk M, Elkayam O.

Respir Care. 2016 Oct;61(10):1369-73. doi: 10.4187/respcare.04706. Epub 2016 Jun 7.

31.

The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study.

Brikman S, Furer V, Wollman J, Borok S, Matz H, Polachek A, Elalouf O, Sharabi A, Kaufman I, Paran D, Elkayam O.

J Rheumatol. 2016 Sep;43(9):1749-54. doi: 10.3899/jrheum.151491. Epub 2016 Jun 1. Erratum in: J Rheumatol. 2019 Jan;46(1):119.

PMID:
27252430
32.

Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).

Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, Pricop L, Mpofu S; FUTURE 1 study group.

Ann Rheum Dis. 2017 Jan;76(1):203-207. doi: 10.1136/annrheumdis-2015-209055. Epub 2016 May 11.

PMID:
27169431
33.

Attitudes of Israeli Rheumatologists to the Use of Medical Cannabis as Therapy for Rheumatic Disorders.

Ablin JN, Elkayam O, Fitzcharles MA.

Rambam Maimonides Med J. 2016 Apr 19;7(2). doi: 10.5041/RMMJ.10239.

34.

Bilateral Neuroretinitis and a Unilateral Superior Hemivein Occlusion with Frosted Branch Angiitis Pattern Presenting Simultaneously in Behçet's Disease.

Schwartz R, Borok S, Goldstein M, Kesler A, Regev K, Elkayam O, Habot-Wilner Z.

Case Rep Ophthalmol. 2016 Mar 9;7(1):141-7. doi: 10.1159/000444214. eCollection 2016 Jan-Apr.

35.

Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases.

Broyde A, Arad U, Madar-Balakirski N, Paran D, Kaufman I, Levartovsky D, Wigler I, Caspi D, Elkayam O.

J Rheumatol. 2016 Feb;43(2):267-72. doi: 10.3899/jrheum.150397. Epub 2016 Jan 15.

PMID:
26773117
36.

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis.

Elalouf O, Elkayam O.

Ther Clin Risk Manag. 2015 Nov 19;11:1719-26. doi: 10.2147/TCRM.S55928. eCollection 2015. Review.

37.

Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.

Furer V, Zisman D, Pokroy-Shapira E, Molad Y, Elkayam O, Paran D.

Scand J Rheumatol. 2016;45(2):103-6. doi: 10.3109/03009742.2015.1074277. Epub 2015 Oct 29.

PMID:
26515057
38.

Influenza vaccination is safe and effective in patients suffering from fibromyalgia syndrome.

Ablin JN, Aloush V, Brill A, Berman M, Barzilai M, Caspi D, Mandelboim M, Levartovsky D, Polachek A, Wolman Y, Paran D, Barkagan M, Elkayam O.

Reumatismo. 2015 Sep 16;67(2):57-61. doi: 10.4081/reumatismo.2015.823.

39.

Immunogenicity and safety of vaccination against seasonal 2012 influenza virus among patients with psoriatic arthritis and psoriasis.

Polachek A, Korobko U, Mader-Balakirski N, Arad U, Levartovsky D, Kaufman I, Anouk M, Litinsky I, Wigler I, Mendelson E, Paran D, Matz H, Caspi D, Mandelboim M, Elkayam O.

Clin Exp Rheumatol. 2015 Mar-Apr;33(2):181-6. Epub 2015 Feb 18.

PMID:
25738420
40.

Galectin-3 is a sensor-regulator of toll-like receptor pathways in synovial fibroblasts.

Arad U, Madar-Balakirski N, Angel-Korman A, Amir S, Tzadok S, Segal O, Menachem A, Gold A, Elkayam O, Caspi D.

Cytokine. 2015 May;73(1):30-5. doi: 10.1016/j.cyto.2015.01.016. Epub 2015 Feb 14.

PMID:
25689620
41.

Decreased diffusion capacity on lung function testing in asymptomatic patients with systemic lupus erythematosus does not predict future lung disease.

Elalouf O, Fireman E, Levartovsky D, Kaufman I, Rogovski O, Elkayam O, Caspi D, Paran D.

Lupus. 2015 Aug;24(9):973-9. doi: 10.1177/0961203314566633. Epub 2015 Jan 16.

PMID:
25595620
42.

The fine line between Takayasu arteritis and giant cell arteritis.

Polachek A, Pauzner R, Levartovsky D, Rosen G, Nesher G, Breuer G, Anouk M, Arad U, Sarvagyl-Maman H, Kaufman I, Caspi D, Elkayam O.

Clin Rheumatol. 2015 Apr;34(4):721-7. doi: 10.1007/s10067-014-2813-x. Epub 2014 Nov 23.

PMID:
25416136
43.

Prevalence of TNF-α blocker immunogenicity in psoriatic arthritis.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, Maman-Sarvagyl H, Kaufman I, Paran D, Feld J, Litinsky I, Wigler I, Caspi D, Elkayam O.

J Rheumatol. 2015 Jan;42(1):73-8. doi: 10.3899/jrheum.140685. Epub 2014 Nov 15.

PMID:
25399390
44.

Systematic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis.

Orbai AM, Weitz J, Siegel EL, Siebert S, Savage LJ, Aydin SZ, Luime JJ, Elkayam O, Neerinckx B, Urbancek S, de Vlam K, Ritchlin CT; GRAPPA Enthesitis Working Group.

J Rheumatol. 2014 Nov;41(11):2290-4. doi: 10.3899/jrheum.140878. Review.

PMID:
25362713
45.
46.

Ultrasound assessment of enthesis thickening in psoriatic arthritis patients treated with adalimumab compared to methotrexate.

Litinsky I, Balbir-Gurman A, Wollman J, Arad U, Paran D, Caspi D, Elkayam O.

Clin Rheumatol. 2016 Feb;35(2):363-70. doi: 10.1007/s10067-014-2753-5. Epub 2014 Jul 31.

PMID:
25073614
47.

An intensive family intervention clinic for reducing childhood obesity.

Endevelt R, Elkayam O, Cohen R, Peled R, Tal-Pony L, Michaelis Grunwald R, Valinsky L, Porath A, Heymann AD.

J Am Board Fam Med. 2014 May-Jun;27(3):321-8. doi: 10.3122/jabfm.2014.03.130243.

48.

[Guidelines for the diagnosis and treatment of the fibromyalgia syndrome].

Ablin JN, Amital H, Ehrenfeld M, Aloush V, Elkayam O, Langevitz P, Mevorach D, Mader R, Sachar T, Amital D, Buskila D; Israeli Rheumatology Association.

Harefuah. 2013 Dec;152(12):742-7, 751, 750. Hebrew.

PMID:
24483001
49.

Tocilizumab in adult-onset Still's disease: the Israeli experience.

Elkayam O, Jiries N, Dranitzki Z, Kivity S, Lidar M, Levy O, Ablin J, Abu-Shakra M, Savargyl-Maman H, Padova H, Caspi D, Rosner I.

J Rheumatol. 2014 Feb;41(2):244-7. doi: 10.3899/jrheum.130881. Epub 2014 Jan 15.

PMID:
24429168
50.

Granulomatosis and polyangiitis: the rituximab option.

Polachek A, Caspi D, Elkayam O.

Isr Med Assoc J. 2013 Mar;15(3):193-4. No abstract available.

Supplemental Content

Loading ...
Support Center